New Approach Methodologies Developer Coalition New Approach Methodologies Developer Coalition (NAMs-DC) launched in the Spring of 2026 to bring together companies developing new
One to Millions Founded in 2026, One to Millions (O2M) advances therapies from individualized breakthroughs to scalable global solutions.
Critical Path for Alpha-1 Antitrypsin Deficiency Critical Path for Alpha-1 Antitrypsin Deficiency CPA-1 is a public-private partnership comprised of industry partners, academic re
Type 1 Diabetes Consortium The T1D Consortium is working to qualify islet autoimmunity antibodies as prognostic biomarkers to be used in the development of t
Critical Path for Rare Neurodegenerative Diseases CP-RND was founded in September 2022 to lead collaborations that advance treatments to improve the lives of those affected by rare
Quantitative Medicine Program In 2008, C-Path embarked on a visionary journey, setting the stage for innovation in model-informed drug development (MIDD). A piv
Critical Path to Therapeutics for the Ataxias Founded in February 2021, CPTA is a public-private partnership that optimizes clinical trials, advances therapeutic developments a
Translational Therapeutics Accelerator The Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) is a global drug discovery and development
